These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23824908)

  • 21. Future of screening for prostate cancer.
    Dahm P
    BMJ; 2017 Sep; 358():j4200. PubMed ID: 28928226
    [No Abstract]   [Full Text] [Related]  

  • 22. Risks of PSA screening now better understood.
    Peres J
    J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
    [No Abstract]   [Full Text] [Related]  

  • 23. What is a "Diagnostic Test Reference Range" Good for?
    Habibzadeh P; Yadollahie M; Habibzadeh F
    Eur Urol; 2017 Nov; 72(5):859-860. PubMed ID: 28558944
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.
    Tikkinen KAO; Dahm P; Lytvyn L; Heen AF; Vernooij RWM; Siemieniuk RAC; Wheeler R; Vaughan B; Fobuzi AC; Blanker MH; Junod N; Sommer J; Stirnemann J; Yoshimura M; Auer R; MacDonald H; Guyatt G; Vandvik PO; Agoritsas T
    BMJ; 2018 Sep; 362():k3581. PubMed ID: 30185545
    [No Abstract]   [Full Text] [Related]  

  • 25. Summaries for patients. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Ann Intern Med; 2013 May; 158(10):I-28. PubMed ID: 23567761
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk stratification in prostate cancer screening.
    Roobol MJ; Carlsson SV
    Nat Rev Urol; 2013 Jan; 10(1):38-48. PubMed ID: 23247693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in Prostate-Specific Antigen Screening and Prostate Cancer Interventions 3 Years After the U.S. Preventive Services Task Force Recommendation.
    Ong MS; Mandl KD
    Ann Intern Med; 2017 Mar; 166(6):451-452. PubMed ID: 28320011
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostate-specific antigen screening, why have the guidelines changed?
    Sountoulides P; Moutzouris G
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1277-81. PubMed ID: 25306859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is Prostate-Specific Antigen Screening "Proven Ineffective Care"?
    Barry MJ; Albertsen PC
    Ann Intern Med; 2016 May; 164(10):687-8. PubMed ID: 26902323
    [No Abstract]   [Full Text] [Related]  

  • 30. USPTF Prostate Cancer Screening Recommendations-A Step in the Right Direction.
    Carroll PR
    JAMA Surg; 2018 Aug; 153(8):701-702. PubMed ID: 29801146
    [No Abstract]   [Full Text] [Related]  

  • 31. Guidance on patient consultation. Current evidence for prostate-specific antigen screening in healthy men and treatment options for men with proven localised prostate cancer.
    Pini G; Collins J; Ghadjar P; Wiklund P
    Curr Urol Rep; 2015 May; 16(5):28. PubMed ID: 25773347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA screening: Back to the future.
    Klein E
    Cleve Clin J Med; 2018 Nov; 85(11):881-883. PubMed ID: 30395520
    [No Abstract]   [Full Text] [Related]  

  • 33. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 34. Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
    Lee DJ; Mallin K; Graves AJ; Chang SS; Penson DF; Resnick MJ; Barocas DA
    J Urol; 2017 Dec; 198(6):1230-1240. PubMed ID: 28552708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.
    Crawford ED; Rosenberg MT; Partin AW; Cooperberg MR; Maccini M; Loeb S; Pettaway CA; Shore ND; Arangua P; Hoenemeyer J; Leveridge M; Leapman M; Pinto P; Thompson IM; Carroll P; Eastham J; Gomella L; Klein EA
    Urology; 2016 Oct; 96():116-120. PubMed ID: 27450937
    [No Abstract]   [Full Text] [Related]  

  • 36. Prostate cancer: USPSTF screening recommendation could lead to greater numbers of avoidable deaths.
    Fenner A
    Nat Rev Urol; 2014 Sep; 11(9):481. PubMed ID: 25112861
    [No Abstract]   [Full Text] [Related]  

  • 37. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
    ;
    Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSA implications and medical management of prostate cancer for the primary care physician.
    Rehsia S; Shayegan B
    Can J Urol; 2012 Oct; 19 Suppl 1():28-35. PubMed ID: 23089345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.
    Otto SJ; Moss SM; Määttänen L; Roobol M; Zappa M; Nelen V; Kwiatkowski M; Villers A; Hugosson J; Sanchez AB; de Koning HJ
    Eur J Cancer; 2010 Nov; 46(17):3053-60. PubMed ID: 21047586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.
    Smith S; Wolanski P
    ANZ J Surg; 2018; 88(7-8):E589-E593. PubMed ID: 29194902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.